U.S. FDA Approves Takeda's HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) -January 16, 2024 at 08:10 am EST

HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase], the Only up to Once Monthly Subcutaneous Immunoglobulin Infusion to Treat CIDP, Can Be Administered by a Healthcare...

Related Keywords

Japan ,United States ,Elisa Butler ,Van Doorn ,Demyelinating Polyneuropathy ,Giles Platford ,Foundation International ,European Medicines Agency ,European Union ,European Union Summary Of Product Characteristics ,Takeda Pharmaceutical Company Limited ,Drug Administration ,European Commission ,Committee For Medicinal Products Human Use ,Exchange Commission ,Plasma Derived Therapies Business ,Medicinal Products ,Human Use ,Recombinant Human Hyaluronidase ,Inflammatory Neuropathy Cause ,Meningitis Syndrome ,Localized Infection ,Related Acute Lung Injury ,Infectious Agents ,Lab Tests ,Inflammatory Demyelinating Polyneuropathy ,European Union Summary ,Product Characteristics ,Annual Report ,Markets ,